Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Levy

Showing results (221-230 of 571) with videos related to

Pageof 58
Sort By:
Multiple Sclerosis and Related Disorders|January 22, 2026
Why don't all adults get multiple sclerosis?Christopher H Hawkes, Gavin Giovannoni, Jeanette Lechner-Scott, et al.
Multiple Sclerosis and Related Disorders|October 23, 2023
Can we improve outcomes in MS around the world? Access and global considerations across income strataE Ann Yeh, Gavin Giovannoni, Chris Hawkes, et al.
Multiple Sclerosis and Related Disorders|April 26, 2022
High efficacy treatment is not enough in MS: Socioeconomic factors are key to improving outcomesE Ann Yeh, Gavin Giovannoni, Chris Hawkes, et al.
Multiple Sclerosis and Related Disorders|November 10, 2023
Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosisNegar Molazadeh, Tetsuya Akaishi, Gauruv Bose, et al.
Journal of Clinical Medicine|June 16, 2019
Deregulation of miRNA in <i>Helicobacter pylori</i>-Induced Gastric MALT Lymphoma: From Mice to HumanAlice Blosse, Michael Levy, Cyrielle Robe, et al.
Journal of Neuroimmunology|September 21, 2021
Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorderNegar Molazadeh, Angeliki G Filippatou, Eleni S Vasileiou, et al.
Multiple Sclerosis and Related Disorders|June 9, 2023
Beyond the B-cell as a treatment target in multiple sclerosisGavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, et al.
Multiple Sclerosis and Related Disorders|December 22, 2022
What are T-cells telling us about how EBV causes MS?Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, et al.
Multiple Sclerosis and Related Disorders|August 15, 2023
Is it ethical to use teriflunomide as an active comparator in phase 3 trials?Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, et al.
Multiple Sclerosis and Related Disorders|March 13, 2026
The case for seronegative MOG antibody syndrome (SMOGAS)Michael Levy, Jeannette Lechner-Scott, Christopher H Hawkes, et al.
Pageof 58

Showing results (221-230 of 571) with videos related to

Sort By:
Pageof 58
Multiple Sclerosis and Related Disorders|January 22, 2026
Why don't all adults get multiple sclerosis?Christopher H Hawkes, Gavin Giovannoni, Jeanette Lechner-Scott, et al.
Multiple Sclerosis and Related Disorders|October 23, 2023
Can we improve outcomes in MS around the world? Access and global considerations across income strataE Ann Yeh, Gavin Giovannoni, Chris Hawkes, et al.
Multiple Sclerosis and Related Disorders|April 26, 2022
High efficacy treatment is not enough in MS: Socioeconomic factors are key to improving outcomesE Ann Yeh, Gavin Giovannoni, Chris Hawkes, et al.
Multiple Sclerosis and Related Disorders|November 10, 2023
Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosisNegar Molazadeh, Tetsuya Akaishi, Gauruv Bose, et al.
Journal of Clinical Medicine|June 16, 2019
Deregulation of miRNA in <i>Helicobacter pylori</i>-Induced Gastric MALT Lymphoma: From Mice to HumanAlice Blosse, Michael Levy, Cyrielle Robe, et al.
Journal of Neuroimmunology|September 21, 2021
Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorderNegar Molazadeh, Angeliki G Filippatou, Eleni S Vasileiou, et al.
Multiple Sclerosis and Related Disorders|June 9, 2023
Beyond the B-cell as a treatment target in multiple sclerosisGavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, et al.
Multiple Sclerosis and Related Disorders|December 22, 2022
What are T-cells telling us about how EBV causes MS?Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, et al.
Multiple Sclerosis and Related Disorders|August 15, 2023
Is it ethical to use teriflunomide as an active comparator in phase 3 trials?Gavin Giovannoni, Christopher H Hawkes, Jeannette Lechner-Scott, et al.
Multiple Sclerosis and Related Disorders|March 13, 2026
The case for seronegative MOG antibody syndrome (SMOGAS)Michael Levy, Jeannette Lechner-Scott, Christopher H Hawkes, et al.
Pageof 58